← Back to Clinical Trials
Recruiting NCT06954337

NCT06954337 MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06954337
Status Recruiting
Phase
Sponsor Memorial Sloan Kettering Cancer Center
Condition Breast Cancer
Study Type INTERVENTIONAL
Enrollment 1,750 participants
Start Date 2025-05-01
Primary Completion 2027-03-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Usual practice pattern (UPP)Experimental: Enhanced Telehealth (ET)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,750 participants in total. It began in 2025-05-01 with a primary completion date of 2027-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Many people with cancer spend a lot of time and money traveling to and from the doctor's office for cancer care. MSK's goal is to make getting cancer care easier by cutting down the need to make in-person visits to MSK. MSK is trying to do this through a new option called enhanced telehealth.

Eligibility Criteria

Inclusion Criteria: * Patients with breast or prostate cancer at Memorial Sloan Kettering Cancer Center who have had at least 3 prior medical oncology visits. Exclusion Criteria: * Patient is enrolled on a therapeutic clinical trial. * Patients whose primary language is not currently supported by Epic.

Contact & Investigator

Central Contact

Erin Bange, MD, MSCE

✉ bangee@mskcc.org

📞 646-422-4680

Principal Investigator

Erin Bange, MD, MSCE

PRINCIPAL INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Frequently Asked Questions

Who can join the NCT06954337 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06954337 currently recruiting?

Yes, NCT06954337 is actively recruiting participants. Contact the research team at bangee@mskcc.org for enrollment information.

Where is the NCT06954337 trial being conducted?

This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.

Who is sponsoring the NCT06954337 clinical trial?

NCT06954337 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Erin Bange, MD, MSCE at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 1,750 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology